Jesper HaaningMSc, PhD
Jesper Haaning holds a MSc in Biology and Ph.D. in Protein Chemistry at Aarhus University. He has since 2011 been employed as a project vice president at Novo Nordisk, where he is responsible for the clinical development of medical products for the treatment of softer. Throughout his career in the pharmaceutical industry, Jesper Haaning has gained a solid experience in all aspects of research and development of protein-based drugs. After his PhD he worked for a short period as an assistant professor at Aarhus University and later as a researcher at M&E Biotech and Maxygen in Denmark. For the past 17 years, Jesper Haaning has been responsible for drug projects and project portfolios primarily within hemostasis. He has long been part of the management of research and development units and from 2008-11 was responsible for Bayer's research portfolio, pharmacology and toxicology units within hematology. Jesper Haaning is a co-author of 11 publications and 35 patents and has supervised students at AU and CBS and has presented at numerous international conferences.